Other substances

Nelfinavir mesylate

An HIV protease inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Nelfinavir Mesylate is the mesylate salt form of nelfinavir, a synthetic antiviral agent that selectively binds to and inhibits human immunodeficiency virus (HIV) protease. Nelfinavir has activity against HIV 1 and 2 (NCIt).

Nelfinavir on DrugBank
Nelfinavir mesylate on PubChem
Nelfinavir on Wikipedia

Marketed as

Viracept

CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O.CS(=O)(=O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model Preprint In silico	in silico			Feb/02/2020
Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19 Preprint Screening	VERO cells			Mar/19/2020
The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections	VERO cells			Apr/24/2020
Multidrug treatment with nelfinavir and cepharanthine against COVID-19	VERO E6 cell cultures		better in combination with cepharanthine	Apr/15/2020
Antiviral options against SARS-CoV-2 infection Preprint Screening	VERO E6 cell cultures		synergistic effect in combination with host-directed drugs, such as salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine	May/12/2020
Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro Preprint	VERO E6 cell cultures		better than lopinavir or tipranavir	Apr/08/2020
Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19 Preprint In vitro Screening	HeLa-ACE2 cells			Jun/16/2020
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19 Preprint Screening	human A549-ACE2 cells			Jun/23/2020
In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials	in silico	3.31	In silico screening of potential SARS-CoV-2 3C-like protease inhibitors.	Aug/05/2020
Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection 3CLpro PapainLpro Enzyme assay Animal model In vitro In silico	in silico; in vitro enzyme assay; Vero E6 cells; golden Syrian hamsters; SARS-CoV-2 clinical isolate hCoV-19/Taiwan/4/2020	9.41	Inhibited SARS-CoV-2 infection in Vero E6 cells (selectivity index of ca. 3.7). Oral administration preceding viral challenge significantly decreased lung viral loads in golden Syrian hamsters. The drug inhibited SARS-CoV-2 3C-like protease in vitro.	Jan/15/2021

AI-suggested references

Link	Publication date
The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections	Aug/30/2020
Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen	Mar/01/2022
Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay	Feb/25/2022

Export (.csv)